跳至主要内容
临床试验/NCT03934177
NCT03934177已完成不适用

Impact of Blueberry Consumption on Intestinal Permeability, Gut Microbiota, and Gut-Derived Inflammation in Individuals With Elevated Risk of a Pro-Inflammatory Gut Milieu

University of Nebraska Lincoln4 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2019年3月26日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
28
试验地点
4
主要终点
intestinal permeability

研究概览

简要总结

This study will evaluate the impact of blueberry consumption on markers of gastrointestinal health including gut microbiota, intestinal permeability, and gut-derived inflammation in those vulnerable to a unhealthy gut milieu. All participants will consume a blueberry powder and a placebo in this crossover study.

详细描述

The commensal bacteria that reside in the human gut, known as the gut microbiota, is a complex system that modulates local gut homeostasis and systemic biological processes. Several environmental factors have been shown to influence the gut milieu (including microbiota), and thus both gastrointestinal and host health. Relevant to the current proposal is the influence of body weight, diet, and circadian rhythms. In the current study, the investigators propose to use these common disruptors of gastrointestinal health through recruiting obese shift workers with a low-fiber diet to identify if these disrupted individuals can benefit from blueberry intake. Specifically, the study objectives are to determine if 24 g whole blueberry powder consumed daily can beneficially modify intestinal permeability, gut microbiota, microbial metabolites, and both gut-derived and systemic inflammation in those most susceptible to a pro-inflammatory milieu. This will be accomplished through a 14-week crossover study in which 28 individuals will be randomized by treatment group order to 4 weeks of whole blueberry powder and placebo powder, with a 4-week wash out in between the treatment periods.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

盲法说明

Participants, investigators, and statistician will blinded to treatment.

入排标准

年龄范围
19 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • obese (BMI +/- 30.0 kg/m2)
  • shift workers (shift work overnight (third shift) +/= 3 days/week for the past 3 months)
  • 19-70 years of age

排除标准

  • patient history of gastrointestinal diseases except for hiatal hernia, GERD, or hemorrhoids, mild gastrointestinal symptoms
  • elevated laboratory values from a comprehensive metabolic panel (CMP) and complete blood count (CBC) with the exception of glucose (+/= 126 mg/dL; if elevated, confirmed with HA1c of greater than or equal to 6.5%) and ALT, AST, or ALP over 2 times normal levels (to allow for mild elevations resulting from fatty liver often seen in obese) unless approved by study physician
  • currently pregnant or plans to become pregnant during the study as determined by participant report
  • antibiotic use within the last 12 weeks prior to enrollment
  • presence of chronic metabolic disease (e.g., cardiovascular disease, diabetes, cancer) or per physician discretion
  • recent (past 4 weeks) major change in dietary habits or a plan to have a major change in dietary habits during the study
  • habitual blueberry consumption of more than 0.5 cups 2x/week or a 4-week washout period if consumes
  • allergy or intolerance to blueberries
  • consumption of supplemental fiber, probiotics or prebiotics without an appropriate 4-week washout period
  • restrictive dietary patterns (e.g., ketogenic, Paleolithic) or a diet high in fiber (+/= 14 g/1000 kilocalories) to increase study result generalizability to the U.S. population (low-fiber diet), as well as provide another stimuli for gut leakiness
  • unwillingness to consent to the study.

结局指标

主要结局

intestinal permeability

时间窗: 28 days

urinary sugar measurement by gas chromatography (GC): Sucralose, lactulose, mannitol, sucrose as a percent of oral dose.

次要结局

  • Microbiota(28 days)
  • Microbial metabolites(28 days)
  • Gut-derived/systemic inflammation(28 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验